Overview

A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

Status:
Completed
Trial end date:
2022-03-28
Target enrollment:
Participant gender:
Summary
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6012 and each component in healthy adult volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Dong Wha Pharmaceutical Co. Ltd.
Treatments:
Dapagliflozin
Sitagliptin Phosphate